ProfileGDS5678 / 1442903_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 62% 62% 62% 62% 61% 61% 60% 68% 61% 62% 67% 65% 64% 64% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 13.7130762
GSM967853U87-EV human glioblastoma xenograft - Control 23.6719562
GSM967854U87-EV human glioblastoma xenograft - Control 33.7156362
GSM967855U87-EV human glioblastoma xenograft - Control 43.6857362
GSM967856U87-EV human glioblastoma xenograft - Control 53.6192361
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.7088661
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.6590260
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 34.1604868
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 43.6319961
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 13.7102162
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 24.047167
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 33.8597865
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 43.8342564
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 53.8264864